BridgeMD
Protocol with Progestin-primed Ovarian Stimulation (PPOS) in conventional treatment from the start of stimulation vs protocol with GnRH antagonists as a pituitary suppressor in patients who are going to undergo DUOSTIM with embryo accumulation for PGT-A of the embryos.
EU CTIS ID: 2023-508769-33-00
What this study is testing
To study whether there is a difference in the number of euploid embryos obtained in two groups of patients who are going to accumulate embryos for PGT-A by means of double ovarian stimulation, comparing two methods of pituitary suppression: the use of gestagens from the beginning of stimulation and the use of GnRH antagonists.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Age less than 43 years . 2. Regular menstrual cycles between 21 and 35 days. 3. Indication for IVF with PGT-A 4. Both ovaries present. 5. Ability to participate and complete the study. 6. Give and sign consent to participate in the study.
You likely can't join if
- 1. Endometriosis grade III/IV 2. Concurrent participation in another study
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.